ACHE and COVID-19: Pyridostigmine, an acetylcholinesterase inhibitor, has been previously shown to decrease inflammation in people living with human immunodeficiency virus (HIV) infection [8–10]; therefore, it is possible that Pyridostigmine may lead to a decrease in the production of pro-inflammatory cytokines in patients with COVID-19 at high risk of severe disease.